|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
7/10/2007 3:11:42 PM
EDMONTON, July 10 /CNW/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Alseres Pharmaceuticals, Inc., (Alseres) a publicly traded (Nasdaq: ALSE - News) Central Nervous System diagnosis and treatment company located in Hopkinton, Massachusetts, U.S.A., announced today the signing of a contract for the process development and cGMP manufacturing of Cethrin(R) for spinal cord injury. QSV will be responsible for technology transfer, process development and cGMP manufacture of phase IIb/III clinical trial material in their commercially licensed cGMP manufacturing facility. Cethrin(R), licensed by Alseres from BioAxone Therapeutics, is a Rho inhibitor that stimulates axon regeneration.
|
|
|
|
|
|
|
|
|
|
|